Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of Debio 4228 in advanced prostate cancer
2024-511038-11-00Phase 2Completed
- Sponsor
- Debiopharm
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of Debio 4228 in prostate cancer (PCa) (4 arms), sponsored by Debiopharm. Primary endpoints: Degarelix plasma pharmacokinetic profile and parameters over 12 weeks after Debio 4228 dosing and Testosterone serum concentration profile. Started Sep 2024; status: completed.
02
Drugs
Debio 4228
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-511038-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511038-11-00.